Latest News

Analyst upgrade puts Kanzhun in focus Bernstein’s upgrade of Kanzhun (NasdaqGS:BZ) following its Q1 2026 results has put the stock back on many investors’ radars, with attention on revenue trends, user metrics, and AI driven matching. See our latest analysis for Kanzhun. The upgrade lands after a mixed stretch for Kanzhun, with the share price up 2.62% over 90 days but down 34.48% year to date and the 1 year total shareholder return declining 22.64%. This suggests recent momentum is tentative...

In recent days, Telix Pharmaceuticals and United Imaging Healthcare signed a memorandum of understanding for a research collaboration in the US to combine United Imaging’s advanced scanner, software and AI platforms with Telix’s molecular imaging products, initially centred on TLX101-Px for characterizing recurrent or progressive glioma under FDA review. This alliance underscores Telix’s push to integrate its radiopharmaceutical pipeline with cutting-edge imaging hardware and clinical...

SNAP restrictions on sugary and highly processed foods are putting fresh attention on health and wellness food stocks, as billions in assisted grocery spending are reconsidered. For investors, this kind of policy shift can change which companies benefit from consumer demand tied to assistance programs and which feel pressure on sales of less nutritious products. This article looks at 3 stocks from a Health and Wellness Food Companies screener that appear more aligned with cleaner labels and...

BioLife Solutions (BLFS) is back in focus after Prosper Stars & Stripes added the stock to its portfolio again, pointing to the company’s renewed emphasis on core biopreservation media as well as cell and gene therapy exposure. See our latest analysis for BioLife Solutions. Recent trading reflects that shift in attention, with BioLife Solutions showing a 35.84% 90 day share price return and a 22.71% 1 year total shareholder return, while the current share price sits at $26.04 as investors...

Skyworks Solutions (SWKS) is back in focus after quarterly revenue and EPS both beat analyst estimates, with CEO Phil Brace pointing to solid execution and improving momentum across the company’s product portfolio as key drivers. See our latest analysis for Skyworks Solutions. At a share price of $72.45, Skyworks Solutions has seen a 32.96% 90 day share price return and a 12.51% year to date share price return, while the 5 year total shareholder return is down 53.17%. This suggests that...

AI is no longer just a story about experiments and cash burn; it is increasingly about companies that turn heavy AI investment into real earnings. With inflation, rates, and energy prices all in focus, many investors are looking for businesses that already know how to convert AI spending into profits instead of promises. The Profitable AI Stocks screener is built for this, highlighting companies that are not only serious about AI but are also earning from it. In this article, you will see 3...

Inflation is back in focus as rising oil and gasoline prices feed into headline data, even while core measures look steadier. For investors, that mix can reshape which stocks carry more risk or potential opportunity as fuel costs, consumer prices, and interest rate expectations interact. This article looks at three Canadian stocks exposed to those inflation drivers, all pulled from our Inflation Impact Plays: Energy, Airlines, and Retail Stocks screener. One appears better placed to benefit...

Clinical PSMA Data Sparks Fresh Look At Vir Biotechnology Stock Vir Biotechnology (VIR) has moved back onto investors' radars after new PSMA clinical data in prostate cancer prompted an updated investment thesis and renewed focus on the company’s T cell engager pipeline. See our latest analysis for Vir Biotechnology. At a share price of US$9.16, Vir Biotechnology’s short term picture reflects a mix of optimism and caution, with a 7 day share price return of 6.39% and a year to date share...

Recently, Hilton Worldwide Holdings reported double-digit year-over-year growth in both revenue and net profit and continued to be recognized for its solid financial position within the Hotels & Entertainment Services industry, while institutional investors increased their aggregate holdings to slightly above the company’s total free float. At the same time, institutional ownership reached the highest score in its industry and Hilton launched a large-scale mentorship and travel-points...

Synovis Micro Companies Alliance, a subsidiary of Baxter International (BAX), has signed an exclusive multi-year deal with MediThinQ to distribute the SHIYA 3D surgical visualization platform globally, expanding Baxter’s footprint in digital surgical technology. See our latest analysis for Baxter International. The MediThinQ agreement arrives after a volatile stretch for Baxter International, with a 19.75% 90 day share price return contrasting with a 33.11% decline in 1 year total shareholder...

SEI Investments (NasdaqGS:SEIC) has created new executive roles to scale its AI and data strategy across the enterprise. The company appointed Matt Provencher as Global Head of Enterprise Professional Services to lead its expanded services organization. SEI is rolling out next generation platforms, AI powered tools, and enterprise wide automation initiatives to support clients. SEI Investments operates at the intersection of technology and investment services, providing platforms and...

Kymera Therapeutics (KYMR) is back in focus after sharing new data on its protein degrader pipeline, including Phase 1 results for KT-621 in healthy Japanese adults and expanded preclinical findings for lupus candidate KT-579. See our latest analysis for Kymera Therapeutics. Kymera Therapeutics’ recent KT-621 and KT-579 readouts arrive after a period of strong momentum, with the latest share price at $90.43, a 30 day share price return of 14.63% and a one year total shareholder return of...

ADT Inc. recently earned two 2026 ConsumerAffairs Buyer’s Choice Awards for Best Customer Service and Best Product Offering, launched its new self-installed ADT Blu home security system, and joined the Board of Directors of the Connectivity Standards Alliance alongside major technology firms. This combination of third-party recognition, a flexible DIY product launch, and a deeper role in shaping smart home standards underscores how ADT is positioning itself at the center of evolving home...

Inflation data, fuel prices and interest rate expectations are moving together in ways that can quickly reshape which Australian stocks look appealing and which might struggle. The extension of the federal fuel excise cut and a modest pullback in headline inflation could ease cost pressures for some companies, while others tied to fuel supply or sensitive to underlying inflation may face tougher conditions. This article breaks down three stocks from the Australian Inflation and Fuel Price...

Earlier in June 2026, American Express completed a €750 million fixed-to-floating rate, callable senior Eurobond offering due June 16, 2034, with Merrill Lynch International, Deutsche Bank AG London, and Morgan Stanley & Co. International acting as co-lead underwriters. This bond issuance, alongside moves such as the planned €700 million cash acquisition of TheFork and a new global NFL partnership, highlights how American Express is using its balance sheet and brand to expand fee-based,...

In recent months, Assured Guaranty has faced operational pressures, including lower net premiums earned, projections for substantially reduced revenue, and a two-year decline in earnings per share. These trends point to sustained challenges in its core credit protection business, raising questions about how effectively the company can sustain its existing earnings profile. We’ll now examine how these operational challenges and weaker earnings trends may alter Assured Guaranty’s earlier...

Charles River Laboratories International stock reacts to new AI drug discovery collaboration Charles River Laboratories International (CRL) is back in focus after a Morgan Stanley upgrade and a new collaboration with Eli Lilly's AI and machine learning drug discovery platform, TuneLab. See our latest analysis for Charles River Laboratories International. The recent Morgan Stanley upgrade and the Lilly TuneLab collaboration arrive as momentum in Charles River Laboratories International’s share...

Vaxcyte (PCVX) recently started dosing participants in a Phase 1 trial of VAX-A1, its investigational Group A Streptococcus vaccine. This development gives investors a fresh clinical milestone to weigh alongside the stock’s recent performance. See our latest analysis for Vaxcyte. The recent VAX-A1 trial news comes as Vaxcyte’s 7-day share price return of 8.39% and 30-day share price return of 8.75% contrast with a softer 90-day share price return. The 1-year total shareholder return of 56.50%...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

In recent days, Victory Capital Holdings reported very high institutional ownership of 95.08%, a strong quarter-over-quarter increase, alongside solid financial health supported by higher quarterly revenue and net profit despite lower operating efficiency. Technical indicators now show the stock trading between clearly defined support and resistance levels with multiple buy signals, highlighting growing institutional confidence combined with active range-based trading interest. We’ll now...

Inflation in India is heating up, with wholesale prices at 9.68% in May and higher crude oil costs feeding through to food, transport, and everyday essentials. For investors, that combination can squeeze many businesses, while others may prove more resilient as households continue to prioritise staples. This article looks at how those pressures and potential policy moves from the RBI or government might affect a group of large and mid-cap consumer staples stocks listed in the US, Canada, the...

Hansoh Pharmaceutical Group (SEHK:3692) has been added to the Hang Seng China Enterprises Index, an index inclusion that can affect how capital flows into the stock as passive funds adjust their holdings. See our latest analysis for Hansoh Pharmaceutical Group. At a latest share price of HK$29.96, Hansoh Pharmaceutical Group has seen its 1 month share price return decline 12.14%, while its 1 year total shareholder return is 8.20% and its 3 year total shareholder return is very large. This...

Global markets are sending mixed messages, with inflation, interest rates, and consumer demand pulling in different directions across regions. In this kind of backdrop, many investors are looking for companies where analysts still expect strong earnings growth and where balance sheets appear solid enough to handle changing conditions. That is exactly what the Healthy high growth potential screener aims to capture, by focusing on forecast earnings strength and basic financial resilience rather...

On June 12, 2026, Werner Enterprises’ Executive Vice President and Chief Administrative Officer Jim Schelble sold 933 shares, leaving him with 70,500.395 shares, while the company reported a year-over-year revenue increase of 13.55% and a net profit increase of 57.79%. This combination of executive share sale and sharp improvements in revenue and profit offers a nuanced view of Werner’s current corporate and financial position. We’ll now examine how Werner’s recent revenue and profit growth...